

# CITATION REPORT

List of articles citing

## CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

DOI: 10.1038/clpt.2010.279

Clinical Pharmacology and Therapeutics, 2011, 89, 464-7.

**Source:** <https://exaly.com/paper-pdf/51033823/citation-report.pdf>

**Version:** 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
795	Personalizing medicine with clinical pharmacogenetics. <b>2011</b> , 13, 987-95		138
794	Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 90, 625-9	6.1	486
793	Cancer pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 90, 461-6	6.1	31
792	Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 90, 328-32	6.1	346
791	Pharmacogenomic Research in South Africa: Lessons Learned and Future Opportunities in the Rainbow Nation. <b>2011</b> , 9, 191-207		49
790	Response to Pharmacogenetics: Call to Action <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 90, 507-508.	6.1	4
789	Pharmacogenetics: call to action. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 90, 507; author reply 507-8	6.1	4
788	Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 89, 455-9	6.1	25
787	Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 89, 387-91	6.1	433
786	Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. <b>2011</b> , 31, 1192-207		37
785	Pharmacogenetics, cost of genotyping, and guidelines for individualizing therapy with mercaptopurine in pediatric acute lymphoblastic leukemia. <b>2011</b> , 57, 1247		0
784	Whole-genome resequencing in pharmacogenomics: moving away from past disparities to globally representative applications. <i>Pharmacogenomics</i> , <b>2011</b> , 12, 1717-28	2.6	21
783	From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. <b>2011</b> , 5, 795-806		128
782	Facilitating clinical implementation of pharmacogenomics. <b>2011</b> , 306, 304-5		46
781	Evolving research and stakeholder perspectives on pharmacogenomics. <b>2011</b> , 306, 1252-3		11
780	Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1. <b>2011</b> , 2, 253-61		11
779	Comment: global formulary review: how do we integrate pharmacogenomic information?. <b>2011</b> , 45, 1030; author reply 1030-1		

778	Allopurinol pharmacogenetics: assessment of potential clinical usefulness. <i>Pharmacogenomics</i> , <b>2011</b> , 12, 1741-9	2.6	30
777	Biomarkers in drug development and regulation: a paradigm for clinical implementation of personalized medicine. <b>2011</b> , 5, 705-13		26
776	Reply: Global Formulary Review: How Do We Integrate Pharmacogenomic Information?. <b>2011</b> , 45, 1030-1031		
775	Pharmacogenetics in perioperative medicine. <b>2012</b> , 25, 419-27		48
774	The challenges of developing a 'medical-grade' genome. <i>Pharmacogenomics</i> , <b>2012</b> , 13, 369-72	2.6	2
773	Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. <i>Pharmacogenomics</i> , <b>2012</b> , 13, 955-62	2.6	22
772	Finding a place for genomics in health disparities research. <b>2012</b> , 15, 156-63		22
771	The public health genomics translation gap: what we don't have and why it matters. <b>2012</b> , 15, 132-8		10
770	On not reinventing the wheel. <b>2012</b> , 44, 233		4
769	Pharmacogenomic Testing in the Asthma Clinic: Will Inhaled Corticosteroids Lead the Way?. <b>2012</b> , 25, 44-47		1
768	Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working group. <b>2012</b> , 1, e000554		9
767	Clinical Pharmacology & Therapeutics 2011: Year in Review. <i>Clinical Pharmacology and Therapeutics</i> , <b>2012</b> , 91, 353-357	6.1	
766	Academia at the crossroads: education and training in pharmacogenomics. <b>2012</b> , 9, 497-506		12
765	Challenges and opportunities in implementing pharmacogenomics testing in the clinics. <b>2012</b> , 9, 609-619		
764	Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. <i>Clinical Pharmacology and Therapeutics</i> , <b>2012</b> , 92, 360-5	6.1	40
763	Personalized medicine: is it a pharmacogenetic mirage?. <b>2012</b> , 74, 698-721		49
762	Epigenetics: a new link toward understanding human disease and drug response. <i>Clinical Pharmacology and Therapeutics</i> , <b>2012</b> , 92, 669-73	6.1	10
761	Clinical pharmacogenomics of warfarin and clopidogrel. <b>2012</b> , 25, 428-38		12

760 Clinical Pharmacogenetics. **2012**, 195-215

759	Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?. <b>2012</b> , 6, 349-62		6
758	The success of pharmacogenomics in moving genetic association studies from bench to bedside: study design and implementation of precision medicine in the post-GWAS era. <i>Human Genetics</i> , <b>2012</b> , 131, 1615-26	6.3	51
757	A new DPYD genotyping assay for improving the safety of 5-fluorouracil therapy. <b>2012</b> , 414, 109-11		10
756	Pharmacogene regulatory elements: from discovery to applications. <b>2012</b> , 4, 45		16
755	Pharmacogenomics of chemotherapeutic susceptibility and toxicity. <b>2012</b> , 4, 90		26
754	The NIH genetic testing registry: a new, centralized database of genetic tests to enable access to comprehensive information and improve transparency. <b>2013</b> , 41, D925-35		107
753	The role of pharmacogenetics in nonmalignant gastrointestinal diseases. <b>2012</b> , 9, 173-84		9
752	Pharmacogenomics knowledge for personalized medicine. <i>Clinical Pharmacology and Therapeutics</i> , <b>2012</b> , 92, 414-7	6.1	1181
751	Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. <i>Clinical Pharmacology and Therapeutics</i> , <b>2012</b> , 92, 437-9	6.1	94
750	NAVAGATE: a rubric to move from pharmacogenomics science to pharmacogenomics practice. <i>Pharmacogenomics</i> , <b>2012</b> , 13, 1307-13	2.6	4
749	Pharmacogenomics and individualized medicine: translating science into practice. <i>Clinical Pharmacology and Therapeutics</i> , <b>2012</b> , 92, 467-75	6.1	148
748	Relating human genetic variation to variation in drug responses. <b>2012</b> , 28, 487-95		58
747	Knowledge integration at the center of genomic medicine. <b>2012</b> , 14, 643-7		25
746	Pharmacogenomic Mechanisms of Drug Toxicity. <b>2012</b> , 285-306		
745	The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. <i>Clinical Pharmacology and Therapeutics</i> , <b>2012</b> , 92, 112-7	6.1	254
744	Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology. <i>Frontiers in Pharmacology</i> , <b>2012</b> , 3, 2	5.6	10
743	Current State and Future Prospects of Direct-to-Consumer Pharmacogenetics. <i>Frontiers in Pharmacology</i> , <b>2012</b> , 3, 152	5.6	28

742	Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain. <b>2012</b> , 3, 273		16
741	Pharmacogenomic considerations in opioid analgesia. <b>2012</b> , 5, 73-87		17
740	Developing a prototype system for integrating pharmacogenomics findings into clinical practice. <i>Journal of Personalized Medicine</i> , <b>2012</b> , 2, 241-56	3.6	16
739	Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine. <b>2012</b> , 4, 367-83		34
738	Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. <i>Pharmacogenomics</i> , <b>2012</b> , 13, 579-94	2.6	54
737	Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 363-70	2.8	28
736	Pharmacogenetics and anaesthesia: the value of genetic profiling. <b>2012</b> , 67, 165-79		111
735	Genomic medicine, precision medicine, personalized medicine: what's in a name?. <i>Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 94, 169-72	6.1	38
734	Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. <i>Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 94, 317-23	6.1	617
733	Pharmacogenomics and cardiovascular disease. <b>2013</b> , 15, 376		9
732	Systems-Based Approach to Drug Response. <b>2013</b> , 1, 171-174		1
731	PharmGKB: the Pharmacogenomics Knowledge Base. <b>2013</b> , 1015, 311-20		173
730	The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis. <b>2013</b> , 2, 183-92		7
729	Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. <b>2013</b> , 104, 1074-82		39
728	Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. <i>Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 94, 640-5	6.1	239
727	Cancer pharmacogenomics: early promise, but concerted effort needed. <b>2013</b> , 339, 1563-6		118
726	Pharmacogenetics in transplant patients: mind the mix. <i>Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 94, 443-4	6.1	2
725	Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. <b>2013</b> , 25, 509-33		54

724	Pharmacogenetics and cardiovascular disease--implications for personalized medicine. <b>2013</b> , 65, 987-1009		93
723	Genomic medicine: a decade of successes, challenges, and opportunities. <b>2013</b> , 5, 189sr4		165
722	[Personalised pharmacogenetics. Evidence-based guidelines and clinical application of pharmacogenetic diagnostics]. <b>2013</b> , 56, 1509-21		6
721	Evaluation of ultra-deep targeted sequencing for personalized breast cancer care. <b>2013</b> , 15, R115		14
720	Stakeholder engagement: a key component of integrating genomic information into electronic health records. <b>2013</b> , 15, 792-801		49
719	Genetic contributions to labor pain and progress. <b>2013</b> , 40, 575-87		7
718	An evaluation of pharmacists' expectations towards pharmacogenomics. <i>Pharmacogenomics</i> , <b>2013</b> , 14, 165-75	2.6	54
717	Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. <b>2013</b> , 18, 273-87		111
716	Translating pharmacogenomics discoveries into the clinic: an implementation framework. <b>2013</b> , 5, 94		6
715	Clinical Genome Sequencing. <b>2013</b> , 102-122		24
714	Cancer pharmacogenomics: strategies and challenges. <b>2013</b> , 14, 23-34		154
713	Pharmacogenomics and heart failure in congenital heart disease. <b>2013</b> , 29, 779-85		1
712	The CLIPMERGE PGx Program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 94, 214-7	6.1	121
711	The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. <i>Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 94, 207-10	6.1	128
710	Pharmacogenetics and Pharmacogenomics. <b>2013</b> , 362-371		
709	Implementing genomic medicine in the clinic: the future is here. <b>2013</b> , 15, 258-67		385
708	Whole genome sequencing: a considered approach to clinical implementation. <b>2013</b> , Chapter 9, Unit9.22		6
707	Management of incidental findings in clinical genomic sequencing. <b>2013</b> , Chapter 9, Unit9.23		19

706	Personalized medicine: challenges and opportunities for translational bioinformatics. <b>2013</b> , 10, 453-462		41
705	Pharmacogenomics. <b>2013</b> ,		3
704	Pharmacogenetics in clinical practice: how far have we come and where are we going?. <i>Pharmacogenomics</i> , <b>2013</b> , 14, 835-43	2.6	53
703	Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. <i>Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 93, 324-5	6.1	263
702	Complexities of CYP2D6 gene analysis and interpretation. <b>2013</b> , 25, 534-53		151
701	Response to "Doubt about the feasibility of preemptive genotyping". <i>Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 93, 234	6.1	2
700	Implementation of a clinical research pharmacogenomics program at an academic medical center: role of the genetics healthcare professional. <i>Pharmacogenomics</i> , <b>2013</b> , 14, 703-6	2.6	11
699	Electronic health record design and implementation for pharmacogenomics: a local perspective. <b>2013</b> , 15, 833-41		76
698	Personalized medicine in cardiology: the time for genotype-guided therapy is now. <b>2013</b> , 9, 459-64		1
697	Community pharmacists' attitudes towards clinical utility and ethical implications of pharmacogenetic testing. <b>2013</b> , 10, 793-800		43
696	Pharmacogenomics in early-phase clinical development. <i>Pharmacogenomics</i> , <b>2013</b> , 14, 1085-97	2.6	37
695	Pharmacogenetic testing: Current Evidence of Clinical Utility. <b>2013</b> , 4, 155-169		25
694	Progressing the utilisation of pharmacogenetics and pharmacogenomics into clinical care. <b>2013</b> , 45, 357-70		3
693	Genomic medicine, health information technology, and patient care. <b>2013</b> , 309, 1467-8		20
692	Opioid therapy pharmacogenomics for noncancer pain: efficacy, adverse events, and costs. <b>2013</b> , 2013, 943014		7
691	Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science. <i>Pharmacogenomics</i> , <b>2013</b> , 14, 1383-7	2.6	8
690	Study Designs in Clinical Pharmacogenetic and Pharmacogenomic Research. <b>2013</b> , 309-341		1
689	Predicting the cost and pace of pharmacogenomic advances: an evidence-based study. <b>2013</b> , 59, 649-57		11

688	Challenges in the pharmacogenomic annotation of whole genomes. <i>Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 94, 211-3	6.1	21
687	Pharmacogenetics in Africa, an Opportunity for Appropriate Drug Dosage Regimens: on the Road to Personalized Healthcare. <b>2013</b> , 2, 45		7
686	Pharmacogenomics. <b>2013</b> , 283-285		1
685	Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. <b>2013</b> , 8, e82562		159
684	Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia. <b>2012</b> , 3, 309		12
683	Governmental and Academic Efforts to Advance the Field of Pharmacogenomics. <b>2013</b> , 63-88		2
682	An ontology-based, mobile-optimized system for pharmacogenomic decision support at the point-of-care. <b>2014</b> , 9, e93769		12
681	Pharmacogenomics: Current State-of-the-Art. <b>2014</b> , 5, 430-43		43
680	Drug and xenobiotic biotransformation in the blood-brain barrier: a neglected issue. <b>2014</b> , 8, 335		28
679	Physician Attitudes toward Adopting Genome-Guided Prescribing through Clinical Decision Support. <i>Journal of Personalized Medicine</i> , <b>2014</b> , 4, 35-49	3.6	34
678	Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. <b>2014</b> , 15, 209-17		265
677	Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. <b>2014</b> , 15, 218-32		124
676	Individualization of drug therapy: an historical perspective. <b>2014</b> , 22, 52		4
675	7th Santorini Conference Biologie Prospective Systems Medicine, Personalized Health and Therapy in collaboration with ESPT. <b>2014</b> , 29,		
674	PharmGKB: The Pharmacogenomics Knowledgebase. <b>2014</b> , 289-306		
673	Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds. <b>2014</b> , 9, 20		5
672	Pilot study: incorporation of pharmacogenetic testing in medication therapy management services. <i>Pharmacogenomics</i> , <b>2014</b> , 15, 1729-1737	2.6	12
671	Clinically relevant cancer biomarkers and pharmacogenetic assays. <b>2014</b> , 20, 65-72		11



670	Pharmacogenomics in Drug Discovery and Development. <b>2014,</b>		1
669	Imputation of TPMT defective alleles for the identification of patients with high-risk phenotypes. <b>2014, 5, 96</b>		8
668	Cleveland Clinic's Center for personalized healthcare: setting the stage for value-based care. <i>Pharmacogenomics</i> , <b>2014, 15, 587-91</b>	2.6	12
667	Implementing Clinical Pharmacogenetics: Point-of-Care and Pre-Emptive Testing. <b>2014, 921-930</b>		
666	The pharmacogenetics of drug metabolizing enzymes in the Lebanese population. <b>2014, 29, 81-90</b>		6
665	Strategies to overcome antileishmanial drugs unresponsiveness. <b>2014, 2014, 646932</b>		33
664	Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update. <i>Clinical Pharmacology and Therapeutics</i> , <b>2014, 95, 499-500</b>	6.1	98
663	Using comparative effectiveness research to remedy health disparities. <b>2014, 3, 177-84</b>		3
662	Development and use of active clinical decision support for preemptive pharmacogenomics. <b>2014, 21, e93-9</b>		148
661	Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project". <b>2014, 166C, 68-75</b>		88
660	Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program. <b>2014, 166C, 76-84</b>		70
659	Genomic architecture of pharmacological efficacy and adverse events. <i>Pharmacogenomics</i> , <b>2014, 15, 2025-48</b>	2.6	18
658	Implementation and utilization of genetic testing in personalized medicine. <b>2014, 7, 227-40</b>		44
657	Considerations for rare variants in drug metabolism genes and the clinical implications. <b>2014, 10, 873-84</b>		16
656	Pharmacogenetics in Jewish populations. <b>2014, 29, 221-33</b>		13
655	Testing for thiopurine methyltransferase status for safe and effective thiopurine administration: a systematic review of clinical guidance documents. <b>2014, 14, 493-502</b>		19
654	Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time--using genomic data to individualize treatment protocol. <b>2014, 89, 25-33</b>		213
653	Utilizing pharmacogenetics in psychiatry: the time has come. <b>2014, 18, 117-9</b>		2

652	Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. <i>Clinical Pharmacology and Therapeutics</i> , <b>2014</b> , 95, 269-80	6.1	53
651	Genome-wide association study: a useful tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics. <b>2014</b> , 20, 2541-52		39
650	Pharmacogenetic biomarkers for predicting drug response. <b>2014</b> , 14, 723-35		7
649	Electronic health record systems: risks and benefits. <b>2014</b> , 21, e1		3
648	PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. <b>2014</b> , 166C, 45-55		169
647	Application of genotype-guided cancer therapy in solid tumors. <i>Pharmacogenomics</i> , <b>2014</b> , 15, 79-93	2.6	17
646	Information technology meets pharmacogenomics: Design specifications of an integrated personalized pharmacogenomics information system. <b>2014</b> ,		3
645	Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. <i>Clinical Pharmacology and Therapeutics</i> , <b>2014</b> , 96, 482-9	6.1	180
644	Confronting the challenges of effective pain management in children following tonsillectomy. <b>2014</b> , 78, 1813-27		45
643	Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program. <i>Pharmacogenomics</i> , <b>2014</b> , 15, 845-56	2.6	6
642	Characterizing genetic variants for clinical action. <b>2014</b> , 166C, 93-104		41
641	Prioritizing genomic applications for action by level of evidence: a horizon-scanning method. <i>Clinical Pharmacology and Therapeutics</i> , <b>2014</b> , 95, 394-402	6.1	39
640	Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs. <i>Pharmacogenomics</i> , <b>2014</b> , 15, 1405-16	2.6	14
639	Metformin pharmacogenomics: current status and future directions. <b>2014</b> , 63, 2590-9		90
638	Potential applications of pharmacogenomics to heart failure therapies. <b>2014</b> , 10, 599-606		3
637	Divided We Fall. <b>2014</b> , 11-20		1
636	Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options. <b>2014</b> , 34, 166-84		53
635	Integrating pharmacogenetic information and clinical decision support into the electronic health record. <b>2014</b> , 21, 522-8		46

634	Usability evaluation of pharmacogenomics clinical decision support aids and clinical knowledge resources in a computerized provider order entry system: a mixed methods approach. <b>2014</b> , 83, 473-83		54
633	Leading the way to genomic medicine. <b>2014</b> , 166C, 1-7		21
632	Surveying Recent Themes in Translational Bioinformatics: Big Data in EHRs, Omics for Drugs, and Personal Genomics. <b>2014</b> , 9, 199-205		15
631	Deciphering next-generation pharmacogenomics: an information technology perspective. <b>2014</b> , 4,		33
630	Race and ethnicity in cancer therapy: what have we learned?. <i>Clinical Pharmacology and Therapeutics</i> , <b>2014</b> , 95, 403-12	6.1	14
629	Cancer Pharmacogenomics. <b>2015</b> , 1, 164-191		
628	Pharmacogenomics and Implications for Nursing Practice. <b>2015</b> , 47, 496-504		14
627	In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. <b>2015</b> , 80, 1122-30		30
626	Pharmacogenomic test that predicts response to $\beta$ agonists in adults with asthma is cost effective. <b>2015</b> , 12, 574-584		1
625	Management of Incidental Findings in Clinical Genomic Sequencing. <b>2015</b> , 87, 9.23.1-9.23.16		3
624	Systematic 3D Screening of Amino Acid Mutations in Pharmacogenes. <b>2015</b> , 12, 209-226		
623	Challenges to integrating pharmacogenetic testing into medication therapy management. <b>2015</b> , 21, 346-52		12
622	Global implementation of genomic medicine: We are not alone. <b>2015</b> , 7, 290ps13		112
621	Integration of Genomics in Primary Care. <b>2015</b> , 128, 1251.e1-5		29
620	Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. <b>2015</b> , 90, 716-29		31
619	Pharmacogenomics in diverse practice settings: implementation beyond major metropolitan areas. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 227-37	2.6	12
618	Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. <b>2015</b> , 277, 167-177		42
617	Development of clinical decision support alerts for pharmacogenomic incidental findings from exome sequencing. <b>2015</b> , 17, 939-42		20

616	The intelligent use and clinical benefits of electronic medical records in multiple sclerosis. <b>2015</b> , 11, 205-11	6
615	Asthma Pharmacogenomics: 2015 Update. <b>2015</b> , 15, 42	16
614	ASHP statement on the pharmacist's role in clinical pharmacogenomics. <i>American Journal of Health-System Pharmacy</i> , <b>2015</b> , 72, 579-81	2.2 74
613	Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population. <b>2015</b> , 36, 535-43	16
612	Progress towards the integration of pharmacogenomics in practice. <i>Human Genetics</i> , <b>2015</b> , 134, 459-65	6.3 25
611	Pharmacogenomic knowledge representation, reasoning and genome-based clinical decision support based on OWL 2 DL ontologies. <b>2015</b> , 15, 12	18
610	EPMA position paper in cancer: current overview and future perspectives. <b>2015</b> , 6, 9	60
609	An inter-professional approach to personalized medicine education: one institution's experience. <b>2015</b> , 12, 129-138	12
608	Translational Pharmacogenetics to Support Pharmacogenetically Driven Clinical Decision Making. <b>2015</b> , 59-73	
607	Clinician Perspectives on Using Pharmacogenomics in Clinical Practice. <b>2015</b> , 12, 339-347	47
606	Prospective participant selection and ranking to maximize actionable pharmacogenetic variants and discovery in the eMERGE Network. <b>2015</b> , 7, 67	11
605	Pharmacogenomics in the clinic. <b>2015</b> , 526, 343-50	455
604	[Codeine--Restrictions on use for children and teenagers]. <b>2015</b> , 140, 1093-5	3
603	CSER and eMERGE: current and potential state of the display of genetic information in the electronic health record. <b>2015</b> , 22, 1231-42	63
602	The Genetic Challenges and Opportunities in Advanced Heart Failure. <b>2015</b> , 31, 1338-50	6
601	Pharmacogenomics of hypertension and heart disease. <b>2015</b> , 17, 586	15
600	Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. <b>2015</b> , 55, 89-106	292
599	The current and potential impact of genetics and genomics on neuropsychopharmacology. <b>2015</b> , 25, 671-81	9

598	Pharmacogenetics of cancer drugs. <b>2015</b> , 66, 65-81		42
597	The promise of psychiatric pharmacogenomics. <b>2015</b> , 77, 29-35		40
596	An update on the pharmacogenetics of treating hypertension. <b>2015</b> , 29, 283-91		26
595	An Architectural Solution for Health Information Exchange. <b>2016</b> , 6, 65-103		
594	Potential utility of precision medicine for older adults with polypharmacy: a case series study. <b>2016</b> , 9, 31-45		18
593	Evaluation of popular drug information resources on clinically useful and actionable pharmacogenomic information. <b>2016</b> , 104, 58-61		6
592	Delivering Pharmacogenetic Testing in the Community Setting. <b>2016</b> , 31, 31-39		
591	Challenges of Identifying Clinically Actionable Genetic Variants for Precision Medicine. <b>2016</b> , 2016,		22
590	Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available. <b>2016</b> , 11, e0164972		40
589	Pharmacogenetics and Pharmacogenomics. <b>2016</b> , 121-137		2
588	Transitioning Pharmacogenomics into the Clinical Setting: Training Future Pharmacists. <i>Frontiers in Pharmacology</i> , <b>2016</b> , 7, 241	5.6	21
587	Implementation of Clinical Pharmacogenomics within a Large Health System: From Electronic Health Record Decision Support to Consultation Services. <b>2016</b> , 36, 940-8		68
586	Integrated patient and tumor genetic testing for individualized cancer therapy. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 99, 143-6	6.1	10
585	Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 99, 172-85	6.1	100
584	Pharmacogenomics: Overview of Applications and Relation to Infusion Therapy. <b>2016</b> , 39, 139-48		
583	Disease-drug database for pharmacogenomic-based prescribing. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 100, 179-90	6.1	14
582	Physician response to implementation of genotype-tailored antiplatelet therapy. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 100, 67-74	6.1	38
581	The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 99, 401-4	6.1	7

580	Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6. <i>Human Mutation</i> , <b>2016</b> , 37, 315-23	4.7	61
579	Genetics of Common Antipsychotic-Induced Adverse Effects. <b>2016</b> , 2, 61-78		42
578	Evidence and resources to implement pharmacogenetic knowledge for precision medicine. <i>American Journal of Health-System Pharmacy</i> , <b>2016</b> , 73, 1977-1985	2.2	52
577	Clinical implementation of genomic medicine: the importance of global collaboration. <b>2016</b> , 1, 349-351		3
576	Precise medical decision making in geriatric anti-depressant therapy. <b>2016</b> , 1, 387-396		4
575	Introducing pharmacogenetic testing with clinical decision support into primary care: a feasibility study. <b>2016</b> , 4, E528-E534		16
574	Pharmacogenetic Testing: Application in Mental Health Prescribing. <b>2016</b> , 22, 185-191		2
573	Next generation sequencing: implications in personalized medicine and pharmacogenomics. <b>2016</b> , 12, 1818-30		63
572	Navigating pleiotropy in precision medicine: pharmacogenes from trauma to behavioral health. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 499-505	2.6	7
571	Advances in understanding genomic markers and pharmacogenetics of Parkinson's disease. <b>2016</b> , 12, 433-48		23
570	Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics (Review). <b>2016</b> , 35, 1891-904		13
569	Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement From the American Heart Association. <b>2016</b> , 9, 448-467		37
568	Precision medicine: from pharmacogenomics to pharmacoproteomics. <b>2016</b> , 13, 25		26
567	Challenges of implementing personalized (precision) medicine: a focus on diabetes. <b>2016</b> , 13, 485-497		5
566	Use of Clinical Decision Support to Tailor Drug Therapy Based on Genomics. <b>2016</b> , 209-226		
565	Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 100, 160-9	6.1	110
564	Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges. <b>2016</b> , 9, 233-245		54
563	Clinical Decision Support Systems. <b>2016</b> ,		6

562	Implementing genomics and pharmacogenomics in the clinic: The National Human Genome Research Institute's genomic medicine portfolio. <b>2016</b> , 253, 225-236		17
561	Role of pharmacogenetics in public health and clinical health care: a SWOT analysis. <b>2016</b> , 24, 1651-1657		17
560	Implementation of a multidisciplinary pharmacogenomics clinic in a community health system. <i>American Journal of Health-System Pharmacy</i> , <b>2016</b> , 73, 1956-1966	2.2	64
559	Implementation of inpatient models of pharmacogenetics programs. <i>American Journal of Health-System Pharmacy</i> , <b>2016</b> , 73, 1944-1954	2.2	23
558	Integrating pharmacogenomics into electronic health records with clinical decision support. <i>American Journal of Health-System Pharmacy</i> , <b>2016</b> , 73, 1967-1976	2.2	77
557	Educational strategies to enable expansion of pharmacogenomics-based care. <i>American Journal of Health-System Pharmacy</i> , <b>2016</b> , 73, 1986-1998	2.2	57
556	Pharmacogenomics to achieve precision medicine. <i>American Journal of Health-System Pharmacy</i> , <b>2016</b> , 73, 1906-1907	2.2	5
555	Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade. <b>2016</b> , 20, 593-603		13
554	Novel Disease-Drug Database Demonstrating Applicability for Pharmacogenomic-Based Prescribing. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 100, 600-602	6.1	
553	Exploring Variation in Known Pharmacogenetic Variants and its Association with Drug Response in Different Mexican Populations. <b>2016</b> , 33, 2644-52		10
552	Dosing recommendations for pharmacogenetic interactions related to drug metabolism. <b>2016</b> , 26, 334-9		9
551	High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial. <b>2016</b> , 71, 309-316		16
550	Pharmacogenetic biomarkers for companion and complementary diagnostics: challenges for clinical practice and regulation. <b>2016</b> , 1, 415-418		
549	The integration and interpretation of pharmacogenomics - a comparative study between the United States of America and Europe: towards better health care. <b>2016</b> , 31, 91-6		1
548	Current status of personalized medicine based on pharmacogenetics in cardiovascular medicine. <b>2016</b> , 1, 5-8		1
547	Pharmacogenomic incidental findings in 308 families: The NIH Undiagnosed Diseases Program experience. <b>2016</b> , 18, 1303-1307		11
546	Integrating electronic health record genotype and phenotype datasets to transform patient care. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 99, 298-305	6.1	19
545	Educational innovations in clinical pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 99, 582-4	6.1	18

544	A Critical Evaluation of Pharmacogenetic Information in Package Inserts for Selected Drugs Marketed in India and Its Comparison With US FDA-Approved Package Inserts. <b>2016</b> , 56, 1232-42		3
543	CYP450 genotyping and cumulative drug-gene interactions: an update for precision medicine. <b>2016</b> , 13, 5-8		5
542	Bringing clinical pharmacogenomics information to pharmacists: A qualitative study of information needs and resource requirements. <b>2016</b> , 86, 54-61		25
541	A prognostic model based on readily available clinical data enriched a pre-emptive pharmacogenetic testing program. <b>2016</b> , 72, 107-15		14
540	Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project. <b>2016</b> , 18, 109-23		70
539	Cardiovascular Pharmacogenomics--Implications for Patients With CKD. <b>2016</b> , 23, 82-90		11
538	Pharmacogenetic Predictors of Response. <b>2016</b> , 882, 191-215		3
537	Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 99, 36-7	6.1	90
536	Novel Biomarkers in the Continuum of Breast Cancer. <b>2016</b> ,		9
535	Advances in therapies and scope for personalized medicine in Alzheimer's disease. <b>2016</b> , 13, 189-199		1
534	[Personalized drug therapy based on genetics. Possibilities and examples from clinical practice]. <b>2016</b> , 57, 289-97		1
533	Physicians' attitudes toward pharmacogenetic testing before and after pharmacogenetic education. <b>2016</b> , 13, 119-127		15
532	Impact of New Genomic Technologies on Understanding Adverse Drug Reactions. <b>2016</b> , 55, 419-36		9
531	Creating a scalable clinical pharmacogenomics service with automated interpretation and medical record result integration - experience from a pediatric tertiary care facility. <b>2017</b> , 24, 74-80		30
530	Prediction of CYP2D6 phenotype from genotype across world populations. <b>2017</b> , 19, 69-76		266
529	The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 102, 502-510	6.1	85
528	Highly personalized reports for personalized drug selection by expert systems as clinical decision support. <b>2017</b> , 14, 93-97		
527	A nationwide survey of pharmacists' perception of pharmacogenetics in the context of a clinical decision support system containing pharmacogenetics dosing recommendations. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 215-225	2.6	26



526	Precision Medicine at the University of Alabama at Birmingham: Laying the Foundational Processes Through Implementation of Genotype-Guided Antiplatelet Therapy. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 102, 493-501	6.1	15
525	The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?. <b>2017</b> , 34, 1544-1550		13
524	Personalized medicine: Genetic risk prediction of drug response. <b>2017</b> , 175, 75-90		26
523	Development of a postgraduate year 2 pharmacy residency in clinical pharmacogenetics. <i>American Journal of Health-System Pharmacy</i> , <b>2017</b> , 74, 409-415	2.2	11
522	Pharmacogenetics in obstetric anesthesia. <b>2017</b> , 31, 23-34		7
521	Medication Risk Mitigation: Coordinating and Collaborating with Health Care Systems, Universities, and Researchers to Facilitate the Design and Execution of Practice-Based Research. <b>2017</b> , 33, 257-281		11
520	Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools. <b>2017</b> , 17, 60		44
519	Are Evidence Standards Different for Genomic- vs. Clinical-Based Precision Medicine? A Quantitative Analysis of Individualized Warfarin Therapy. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 102, 805-814	6.1	5
518	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 102, 397-404	6.1	320
517	Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 102, 859-869	6.1	48
516	Engaging Hmong adults in genomic and pharmacogenomic research: Toward reducing health disparities in genomic knowledge using a community-based participatory research approach. <b>2017</b> , 8, 117-125		19
515	Genomic Medicine in Primary Care. <b>2017</b> , 1-18		1
514	Pharmacogenetics and Pharmacogenomics. <b>2017</b> , 89-107		3
513	Design and evaluation of a pharmacogenomics information resource for pharmacists. <b>2017</b> , 24, 822-831		5
512	Local and Global Challenges in the Clinical Implementation of Precision Medicine. <b>2017</b> , 105-117		
511	Drug voyager: a computational platform for exploring unintended drug action. <b>2017</b> , 18, 131		8
510	Electronic Medical Record-Integrated Pharmacogenomics and Related Clinical Decision Support Concepts. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 102, 254-264	6.1	48
509	The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting. <b>2017</b> , 10, 143-146		54

508	An update on HLA alleles associated with adverse drug reactions. <b>2017</b> , 32, 73-87		15
507	Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 101, 341-358 <sup>6.1</sup>		157
506	Time to revisit warfarin pharmacogenetics. <b>2017</b> , 13, 511-513		7
505	Simplifying the use of pharmacogenomics in clinical practice: Building the genomic prescribing system. <b>2017</b> , 75, 110-121		26
504	Primer in Genetics and Genomics, Article 5-Further Defining the Concepts of Genotype and Phenotype and Exploring Genotype-Phenotype Associations. <b>2017</b> , 19, 576-585		1
503	The challenges of implementing pharmacogenomic testing in the clinic. <b>2017</b> , 17, 567-577		28
502	Pharmacogenetics: a general review on progress to date. <b>2017</b> , 124, 65-79		26
501	Pharmacogenomics Implementation at the National Institutes of Health Clinical Center. <b>2017</b> , 57 Suppl 10, S67-S77		14
500	Variant Interpretation: Functional Assays to the Rescue. <b>2017</b> , 101, 315-325		171
499	Primary care physician experiences with integrated pharmacogenomic testing in a community health system. <b>2017</b> , 14, 389-400		30
498	Institutional profile of pharmacogenetics within University of Michigan College of Pharmacy. <i>Pharmacogenomics</i> , <b>2017</b> ,	2.6	1
497	Collaborative Counseling Considerations for Pharmacogenomic Tests. <b>2017</b> , 37, 990-999		24
496	New Pharmacogenomics Research Network: An Open Community Catalyzing Research and Translation in Precision Medicine. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 102, 897-902	6.1	24
495	Prior opioid exposure influences parents' sharing of their children's CYP2D6 research results. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 1199-1213	2.6	2
494	Implementation of a Standardized Medication Therapy Management Plus Approach within Primary Care. <b>2017</b> , 30, 701-714		15
493	The Relationship of Genetics, Nursing Practice, and Informatics Tools in 6-Mercaptopurine Dosing in Pediatric Oncology [Formula: see text]. <b>2017</b> , 34, 342-346		0
492	Challenges and strategies for implementing genomic services in diverse settings: experiences from the Implementing GeNomics In practICE (IGNITE) network. <b>2017</b> , 10, 35		61
491	Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe. <b>2017</b> , 10, 47		18

490	Pharmacogenomic implications of the evolutionary history of infectious diseases in Africa. <b>2017</b> , 17, 112-120	19
489	Pharmacogenomics competencies in pharmacy practice: A blueprint for change. <b>2017</b> , 57, 120-125	39
488	Rapid screening for targeted genetic variants via high-resolution melting curve analysis. <b>2017</b> , 55, 507-516	5
487	Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review. <b>2017</b> , 64, 45-64	24
486	The role of hospital pharmacists in the adoption and use of pharmacogenomics and precision medicine. <b>2017</b> , 14, 27-35	16
485	Advances and challenges in hereditary cancer pharmacogenetics. <b>2017</b> , 13, 73-82	7
484	Multidisciplinary model to implement pharmacogenomics at the point of care. <b>2017</b> , 19, 421-429	54
483	Parental Perception of Self-Empowerment in Pediatric Pharmacogenetic Testing: The Reactions of Parents to the Communication of Actual and Hypothetical CYP2D6 Test Results. <b>2017</b> , 32, 1104-1111	4
482	Predicting CYP2D6 phenotype from resting brain perfusion images by gradient boosting. <b>2017</b> , 259, 16-24	8
481	Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice. <b>2017</b> , 20, 54-59	33
480	Physicians' pharmacogenomics information needs and seeking behavior: a study with case vignettes. <b>2017</b> , 17, 113	11
479	Pharmacogenetic Variation in Over 100 Genes in Patients Receiving Acenocumarol. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 863	5.6 4
478	Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children. <i>Journal of Personalized Medicine</i> , <b>2017</b> , 7,	3.6 19
477	Big Data Analytics for Genomic Medicine. <b>2017</b> , 18,	92
476	Proposed guidelines to evaluate scientific validity and evidence for genotype-based dietary advice. <b>2017</b> , 12, 35	72
475	The Value of Pharmacogenomic Information. <b>2017</b> ,	1
474	Updating the landscape of direct-to-consumer pharmacogenomic testing. <b>2017</b> , 10, 229-232	8
473	State of Art of Cancer Pharmacogenomics in Latin American Populations. <b>2017</b> , 18,	16

472	Pharmacogenetic Information in Clinical Guidelines: The European Perspective. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 795-801	6.1	38
471	PharmGKB: A worldwide resource for pharmacogenomic information. <b>2018</b> , 10, e1417		117
470	Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular Pathology. <b>2018</b> , 20, 269-276		69
469	Hypertension Management for the Prevention of Heart Failure: Best Strategies. <b>2018</b> , 12, 1		
468	A nationwide cross-sectional survey of pharmacy students on pharmacogenetic testing in The Netherlands. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 311-319	2.6	9
467	Genetic Contributions and Personalized Medicine. <b>2018</b> , 3-16		0
466	Significance of Pharmacogenomics in Precision Medicine. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 732-735	6.1	7
465	Pharmacogenomics and big genomic data: from lab to clinic and back again. <b>2018</b> , 27, R72-R78		19
464	Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. <b>2018</b> , 14, 447-460		62
463	Value of Supportive Care Pharmacogenomics in Oncology Practice. <b>2018</b> , 23, 956-964		10
462	Clinical pharmacogenomics testing in the era of next generation sequencing: challenges and opportunities for precision medicine. <b>2018</b> , 18, 411-421		16
461	Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 787-794	6.1	52
460	Effective long-term solution to therapeutic remission in Inflammatory Bowel Disease: Role of Azathioprine. <i>Biomedicine and Pharmacotherapy</i> , <b>2018</b> , 100, 8-14	7.5	11
459	Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population. <b>2018</b> , 38, 205-216		14
458	Pharmacogenomic survey of Qatari populations using whole-genome and exome sequences. <b>2018</b> , 18, 590-600		11
457	Mindful Pharmacogenetics: Drug Dosing for Mental Health. <b>2018</b> , 175, 395-397		4
456	Pharmacogenomics of blood lipid regulation. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 651-665	2.6	1
455	Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation. <b>2018</b> , 122, 1176-1190		15

454	Professional opportunity for pharmacists to integrate pharmacogenomics in medication therapy. <b>2018</b> , 151, 167-169		6
453	CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction. <b>2018</b> , 18, 232-237		9
452	Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 599-618 <sup>6.1</sup>		113
451	Patient Decisions to Receive Secondary Pharmacogenomic Findings and Development of a Multidisciplinary Practice Model to Integrate Results Into Patient Care. <b>2018</b> , 11, 71-76		11
450	Precision Medicine Is Not Just Genomics: The Right Dose for Every Patient. <b>2018</b> , 58, 105-122		48
449	BCRP/ABCG2 and high-alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications. <b>2018</b> , 147, 201-210		45
448	Point-of-care companion diagnostic tests for personalizing psychiatric medications: fulfilling an unmet clinical need. <b>2017</b> , 12, 017101		4
447	PharmCAT: A Pharmacogenomics Clinical Annotation Tool. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 104, 19-22	6.1	24
446	Biomarkers: Delivering on the expectation of molecularly driven, quantitative health. <b>2018</b> , 243, 313-322		7
445	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 210-216	6.1	226
444	Pharmacists advancing role in pharmacogenomics. <b>2018</b> , 58, 592-593		
443	. <b>2018</b> ,		
442	Integration of Germline Pharmacogenetics Into a Tumor Sequencing Program. <b>2018</b> , 2,		7
441	Precision medicine and pharmacogenomics in community and primary care settings. <b>2018</b> , 24, 55-68		6
440	Multidisciplinary Authorship Among Infectious Diseases Society of America Clinical Practice Guidelines: Examining the Contributions of Infectious Diseases Pharmacists. <b>2018</b> , 5, ofy287		3
439	Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 1269-1284	2.6	8
438	Clinical Pharmacogenetics for Precision Medicine: Successes and Setbacks. <b>2018</b> , 3, 474-486		1
437	Building Evidence for Clinical Use of Pharmacogenomics and Reimbursement for Testing. <b>2018</b> , 1, 125-134		3

436	Precision pharmacotherapy: psychiatry's future direction in preventing, diagnosing, and treating mental disorders. <b>2018</b> , 11, 211-222		17
435	Pharmacogenetic testing in oncology: a Brazilian perspective. <b>2018</b> , 73, e565s		4
434	Implementing Clinical Pharmacogenomics in the Classroom: Student Pharmacist Impressions of an Educational Intervention Including Personal Genotyping. <b>2018</b> , 6,		9
433	Implementing a personalized medicine program in a community health system. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 1345-1356	2.6	10
432	Pharmacogenetic content of commercial genome-wide genotyping arrays. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 1159-1167	2.6	5
431	Pharmacogenetics in Cardiovascular Medicine. <b>2018</b> , 83, 333-360		4
430	The impact of real-world cardiovascular-related pharmacogenetic testing in an insured population. <b>2018</b> , 72, e13088		2
429	Clinical Pharmacogenomics: Applications in Nephrology. <b>2018</b> , 13, 1561-1571		10
428	microRNAs and response to statins in patients with hypercholesterolemia: from basic research to precision medicine. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 748-751	2.6	2
427	Systematic evaluation of clinical practice guidelines for pharmacogenomics. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 693-700	2.6	3
426	Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy. <b>2018</b> , 298, 125-132		5
425	Genetic polymorphisms in very important pharmacogenomic variants in the Zhuang ethnic group of Southwestern China: A cohort study in the Zhuang population. <b>2018</b> , 97, e0559		3
424	Evaluation of buccal swabs for pharmacogenetics. <b>2018</b> , 11, 382		3
423	Genetic Programming of Hypertension. <b>2017</b> , 5, 285		20
422	The impact of pharmacokinetic gene profiles across human cancers. <b>2018</b> , 18, 577		1
421	Teaching students in clinical programs about pharmacogenomics: do they understand drug-drug interactions?. <b>2018</b> , 15, 347-350		3
420	Pharmacogenomics of CYP2C9: Functional and Clinical Considerations. <i>Journal of Personalized Medicine</i> , <b>2017</b> , 8,	3.6	86
419	Precision dosing in clinical medicine: present and future. <b>2018</b> , 11, 743-746		38

418	Out-compute drug side effects: Focus on cytochrome P450 2D6 modeling. <b>2018</b> , 8, e1366		4
417	Patient Care Situations Benefiting from Pharmacogenomic Testing. <b>2018</b> , 6, 43-51		1
416	Translating Genomic Information to Rationalize Drug Use. <b>2018</b> , 157-178		
415	Pharmacogenomics, precision medicine, and implications for anesthesia care. <b>2018</b> , 32, 61-81		10
414	Physician-Reported Benefits and Barriers to Clinical Implementation of Genomic Medicine: A Multi-Site IGNITE-Network Survey. <i>Journal of Personalized Medicine</i> , <b>2018</b> , 8,	3.6	60
413	Antidepressant Prescribing in the Precision Medicine Era: a Prescriber's Primer on Pharmacogenetic Tools. <b>2018</b> , 16, 219-224		
412	Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 847-860	2.6	42
411	Implementation of Pharmacogenomics in Everyday Clinical Settings. <b>2018</b> , 83, 219-246		17
410	Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee. <b>2019</b> , 21, 382-390		13
409	Public Chemical Databases. <b>2019</b> , 628-639		2
408	Population Analysis of Pharmacogenetic Polymorphisms. <b>2019</b> , 379-387		
407	Pharmacogenomic Testing: Clinical Evidence and Implementation Challenges. <i>Journal of Personalized Medicine</i> , <b>2019</b> , 9,	3.6	29
406	The "All of Us" Research Program. <b>2019</b> , 381, 668-676		325
405	Colorectal cancer: pharmacogenetics support for the correct drug prescription. <i>Pharmacogenomics</i> , <b>2019</b> , 20, 741-763	2.6	1
404	Pharmacogenomics. <b>2019</b> , 394, 521-532		135
403	Pharmacogenes (PGx-genes): Current understanding and future directions. <b>2019</b> , 718, 144050		9
402	Technical, Biological, and Systems Barriers for Molecular Clinical Decision Support. <b>2019</b> , 39, 281-294		1
401	Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 313-316	6.1	6

400	Leaving some behind: the growing gap in precision medicine for minority populations. <b>2019</b> , 4, 3-5		1
399	A Practical First Step Using Needs Assessment and a Survey Approach to Implementing a Clinical Pharmacogenomics Consult Service. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , <b>2019</b> , 2, 214-221	1.4	1
398	Genetics of high-dose methotrexate-induced oral mucositis: current perspectives. <i>Pharmacogenomics</i> , <b>2019</b> , 20, 621-623	2.6	3
397	Consequences of Copy-Number Variation for Pharmacogenomics in Psychiatry. <b>2019</b> , 10, 432		20
396	Pharmacogenomics-based practice in North Cyprus: its adoption by pharmacists and their attitudes and knowledge. <b>2019</b> , 41, 1299-1306		2
395	Inconsistency in race and ethnic classification in pharmacogenetics studies and its potential clinical implications. <b>2019</b> , 12, 107-123		29
394	Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good. <b>2019</b> , 13, 39		63
393	Use of Pharmacogenetic Drugs by the Dutch Population. <b>2019</b> , 10, 567		9
392	Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications. <b>2019</b> , 19, 501-515		9
391	Variation in Actionable Pharmacogenetic Markers in Natives and Mestizos From Mexico. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 1169	5.6	7
390	Breed Differences and Pharmacogenetics. <b>2019</b> , 95-107		1
389	Pharmacogenomics In Pharmacy Practice: Current Perspectives. <b>2019</b> , 8, 97-104		9
388	Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention. <b>2019</b> , 22, 1231-1239		4
387	The Evolution of DNA Sequencing in Pharmacogenomics. <b>2019</b> , 2, 119-131		1
386	The Three Ps: Psychiatry, Pharmacy, and Pharmacogenomics, a Brief Report From New Zealand. <b>2019</b> , 10, 690		7
385	Pharmacogenomic considerations for medications in the perioperative setting. <i>Pharmacogenomics</i> , <b>2019</b> , 20, 813-827	2.6	4
384	Evolution of Next Generation Therapeutics: Past, Present, and Future of Precision Medicines. <b>2019</b> , 12, 560-563		0
383	Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials. <i>Journal of Personalized Medicine</i> , <b>2019</b> , 9,	3.6	1



382	Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline. <b>2019</b> , 15, 751-765		
381	Governmental and Academic Efforts to Advance the Field of Pharmacogenomics. <b>2019</b> , 55-80		
380	A Look to the Future. <b>2019</b> , 271-288		
379	Pharmacogenomics Education and Clinical Practice Guidelines. <b>2019</b> , 395-414		2
378	The ACCOuNT Consortium: A Model for the Discovery, Translation, and Implementation of Precision Medicine in African Americans. <b>2019</b> , 12, 209-217		17
377	Non-interventional cardiologists' perspectives on the role of pharmacogenomic testing in cardiovascular medicine. <b>2019</b> , 16, 123-132		6
376	Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants. <i>Journal of Personalized Medicine</i> , <b>2019</b> , 9,	3.6	37
375	Star Allele-Based Haplotyping versus Gene-Wise Variant Burden Scoring for Predicting 6-Mercaptopurine Intolerance in Pediatric Acute Lymphoblastic Leukemia Patients. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 654	5.6	13
374	A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care. <b>2019</b> , 27, 1532-1541		21
373	Pharmacogenetic testing in primary care practice: opinions of physicians, pharmacists and patients. <i>Pharmacogenomics</i> , <b>2019</b> , 20, 589-598	2.6	25
372	Pharmacoeugenetics of Major Depression. <b>2019</b> , 747-754		
371	Implementation and obstacles of pharmacogenetics in clinical practice: An international survey. <b>2019</b> , 85, 2076-2088		14
370	Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact. <b>2019</b> , 10,		30
369	Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users. <b>2019</b> , 2, e195345		43
368	Precision Pharmacotherapy: Integrating Pharmacogenomics into Clinical Pharmacy Practice. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , <b>2019</b> , 2, 303-313	1.4	19
367	Precision medicine: a call for increased pharmacogenomic education. <b>2019</b> , 16, 233-245		8
366	Implementing pharmacogenetic testing in rural primary care practices: a pilot feasibility study. <i>Pharmacogenomics</i> , <b>2019</b> , 20, 433-446	2.6	7
365	Pharmacogenomics guidelines: Current status and future development. <b>2019</b> , 46, 689-693		12

364	CYP2D6 testing to guide risperidone and aripiprazole therapy. <b>2019</b> , 6, 362-364		4
363	Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 866-873	6.1	43
362	Pharmacogenomic potential in advanced cancer patients. <i>American Journal of Health-System Pharmacy</i> , <b>2019</b> , 76, 415-423	2.2	3
361	Contemporary pharmacogenetic assays in view of the PharmGKB database. <i>Pharmacogenomics</i> , <b>2019</b> , 20, 261-272	2.6	4
360	Precision medicine in Thailand. <b>2019</b> , 181, 245-253		9
359	Personal genome testing on physicians improves attitudes on pharmacogenomic approaches. <b>2019</b> , 14, e0213860		4
358	An ancillary genomics system to support the return of pharmacogenomic results. <b>2019</b> , 26, 306-310		12
357	Pharmacogenomics and Infectious Diseases in Africa. <b>2019</b> , 95-127		
356	Estimating the Potential Impact of and Genetic Testing on Protocol-Based Care for Depression in Canada and the United States. <b>2020</b> , 5, 27-33		1
355	Depressive Disorders: Mechanisms, Measurement and Management. <b>2019</b> ,		2
354	A multiplex pharmacogenetics assay using the MinION nanopore sequencing device. <b>2019</b> , 29, 207-215		3
353	Precision medicine and future of cancer treatment. <b>2019</b> , 2, 33-33		6
352	A Glimpse into Pharmacogenomics in Africa. <b>2019</b> , 128-167		2
351	Whole genome sequencing identifies high-impact variants in well-known pharmacogenomic genes. <b>2019</b> , 19, 127-135		3
350	Pharmacogenomics: Success and Challenges. <b>2019</b> , 595-606		
349	Pharmacogenomics research and clinical implementation in Brazil. <b>2019</b> , 124, 538-549		8
348	Essential Characteristics of Pharmacogenomics Study Publications. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 105, 86-91	6.1	9
347	An economic model of the cost-utility of pre-emptive genetic testing to support pharmacotherapy in patients with major depression in primary care. <b>2019</b> , 19, 480-489		6

346	The importance of buprenorphine research in the opioid crisis. <b>2019</b> , 24, 626-632		11
345	What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing. <b>2019</b> , 21, 17		14
344	Farmacogenética: la medicina personalizada. <b>2019</b> , 12, 147-154		
343	Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel. <b>2019</b> , 32, 7-15		77
342	Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White?. <b>2019</b> , 59, 577-603		12
341	Commercial Pharmacogenetic Tests in Psychiatry: Do they Facilitate the Implementation of Pharmacogenetic Dosing Guidelines?. <i>Pharmacopsychiatry</i> , <b>2020</b> , 53, 174-178	2	6
340	The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 171-175	6.1	75
339	A pediatric perspective on genomics and prevention in the twenty-first century. <b>2020</b> , 87, 338-344		2
338	Integrating pharmacogenomics into the electronic health record by implementing genomic indicators. <b>2020</b> , 27, 154-158		10
337	Gene-Based Dose Optimization in Children. <b>2020</b> , 60, 311-331		11
336	Repurposing of Diagnostic Whole Exome Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 617-627	6.1	9
335	Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 1240-1255	6.1	25
334	PharmVar GeneFocus: CYP2D6. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 154-170	6.1	84
333	Potential Clinical Relevance of Differences in Allele Frequencies Found within Very Important Pharmacogenes between Hmong and East Asian Populations. <b>2020</b> , 40, 142-152		5
332	CYP2D6 Genotype-guided Metoprolol Therapy in Cardiac Surgery Patients: Rationale and Design of the Pharmacogenetic-guided Metoprolol Management for Postoperative Atrial Fibrillation in Cardiac Surgery (PREEMPTIVE) Pilot Study. <b>2020</b> , 34, 20-28		2
331	PharmGKB summary: very important pharmacogene information for CACNA1S. <b>2020</b> , 30, 34-44		2
330	Pharmacogenetic Testing: The Ethics of Implementing in Clinical Practice for Chronic Pain Patients. <b>2020</b> , 34, 69-76		
329	Clarity Also Needed for Direct-to-Consumer Pharmacogenetic Tests. <b>2020</b> , 38, 283-284		2

328	Engaging in building the educational support needed to deliver precision health in Canada. <b>2020</b> , 33, 135-139		1
327	Current status of cancer pharmacogenomics. <b>2020</b> , 233-243		
326	PharmVar and the Landscape of Pharmacogenetic Resources. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 43-46	6.1	16
325	Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention. <b>2020</b> , 13, 473-481		8
324	Drug Prescribing and Outcomes After Pharmacogenomic Testing in a Developmental and Behavioral Health Pediatric Clinic. <b>2020</b> , 41, 65-70		1
323	Pharmacogenomic Characterization in Bipolar Spectrum Disorders. <b>2019</b> , 12,		4
322	Precision Medicine Using Pharmacogenomic Panel-Testing. <b>2020</b> , 3, 131-142		
321	Patients' Perspectives on Psychiatric Pharmacogenetic Testing. <i>Pharmacopsychiatry</i> , <b>2020</b> , 53, 256-261	2	5
320	Pharmacogenomics in kidney transplant recipients and potential for integration into practice. <b>2020</b> , 45, 1457-1465		
319	Knowledge, Attitudes, and Perceived Barriers toward Genetic Testing and Pharmacogenomics among Healthcare Workers in the United Arab Emirates: A Cross-Sectional Study. <i>Journal of Personalized Medicine</i> , <b>2020</b> , 10,	3.6	4
318	Development of Customizable Implementation Guides to Support Clinical Adoption of Pharmacogenomics: Experiences of the Implementing GeNomics In pracTice (IGNITE) Network. <b>2020</b> , 13, 217-226		5
317	Pharmacogenomics, concepts for the future of perioperative medicine and pain management: A review. <b>2020</b> , 34, 651-662		2
316	Design and Early Implementation Successes and Challenges of a Pharmacogenetics Consult Clinic. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	15
315	genotype-guided antiplatelet therapy: promises and pitfalls. <i>Pharmacogenomics</i> , <b>2020</b> , 21, 889-897	2.6	4
314	Pharmacogenetics in psychiatric care, a call for uptake of available applications. <b>2020</b> , 292, 113336		6
313	Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. <b>2020</b> , 30, 131-144		10
312	Barriers to Implementing Clinical Pharmacogenetics Testing in Sub-Saharan Africa. A Critical Review. <b>2020</b> , 12,		8
311	ASHP Therapeutic Position Statement on the Use of Antipsychotic Medications in the Treatment of Adults with Schizophrenia and Schizoaffective Disorder. <i>American Journal of Health-System Pharmacy</i> , <b>2020</b> , 77, 2114-2132	2.2	1

310	Pharmacogenomics as a Tool to Limit Acute and Long-Term Adverse Effects of Chemotherapeutics: An Update in Pediatric Oncology. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 1184	5.6	3
309	Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	36
308	Pharmacogenomics-guided opioid management. <b>2020</b> , 10, 374-378		2
307	Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization. <b>2020</b> , 12,		4
306	Phenotype prediction and characterization of 25 pharmacogenes in Thais from whole genome sequencing for clinical implementation. <b>2020</b> , 10, 18969		5
305	Prevalence and types of inconsistencies in clinical pharmacogenetic recommendations among major U.S. sources. <b>2020</b> , 5, 48		5
304	Translating pharmacogenetics from research to routine clinical practice via survey of the IGNITE Network. <b>2020</b> , 5,		
303	PG-path: Modeling and personalizing pharmacogenomics-based pathways. <b>2020</b> , 15, e0230950		1
302	Pharmacogenomics and Psychopharmacology. <b>2020</b> , 151-202		2
301	Re: Pharmacogenetic Testing Options Relevant to Psychiatry in Canada. <b>2020</b> , 65, 584-585		1
300	Biomedical Data Science and Informatics Challenges to Implementing Pharmacogenomics with Electronic Health Records. <b>2020</b> , 3, 289-314		7
299	How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 108, 557-565	6.1	10
298	Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient care. <b>2020</b> ,		6
297	Cost avoidance related to a pharmacist-led pharmacogenomics service for the Program of All-inclusive Care for the Elderly. <i>Pharmacogenomics</i> , <b>2020</b> , 21, 651-661	2.6	7
296	Genotype and Phenotype Concordance for Pharmacogenetic Tests Through Proficiency Survey Testing. <b>2020</b> , 144, 1057-1066		1
295	Opinion, experience and educational preferences concerning pharmacogenomics: an exploratory study of Quebec pharmacists. <i>Pharmacogenomics</i> , <b>2020</b> , 21, 235-245	2.6	3
294	Health Economics Tools and Precision Medicine: Opportunities and Challenges. <b>2020</b> , 23,		6
293	Assessing the Implementation of Pharmacogenomic Panel-Testing in Primary Care in the Netherlands Utilizing a Theoretical Framework. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	9

292	Primary Care Prescription Drug Use and Related Actionable Drug-Gene Interactions in the Danish Population. <b>2020</b> , 13, 798-806		2
291	Genetic Influence on Efficacy of Pharmacotherapy for Pediatric Attention-Deficit/Hyperactivity Disorder: Overview and Current Status of Research. <b>2020</b> , 34, 389-414		5
290	Assessment of healthcare professionals' knowledge, attitudes, and perceived challenges of clinical pharmacogenetic testing in Egypt. <b>2020</b> , 17, 251-260		13
289	Homozygote CRIM1 variant is associated with thiopurine-induced neutropenia in leukemic patients with both wildtype NUDT15 and TPMT. <b>2020</b> , 18, 265		2
288	Pharmacogenomics for immunotherapy and immune-related cardiotoxicity. <b>2020</b> , 29, R186-R196		2
287	Response to: Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia. <b>2020</b> , 158, 104838		2
286	Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine. <b>2020</b> , 25, 813-820		13
285	Pharmacogenetics in primary care. <b>2020</b> , 33, 97-101		1
284	Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada. <b>2020</b> , 65, 521-530		15
283	Clinical implementation of pharmacogenomics via a health system-wide research biobank: the University of Colorado experience. <i>Pharmacogenomics</i> , <b>2020</b> , 21, 375-386	2.6	16
282	Current state assessment survey of challenges of pharmacogenomics within oncology pharmacy practice. <b>2020</b> , 26, 1374-1381		
281	Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug-Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients. <i>Journal of Personalized Medicine</i> , <b>2020</b> , 10,	3.6	6
280	Pharmacogenomics. <b>2020</b> , 7, 321-353		1
279	Evaluation of clinical impact of pharmacogenomics knowledge involved in CPIC guidelines on Chinese pediatric patients. <i>Pharmacogenomics</i> , <b>2020</b> , 21, 209-219	2.6	3
278	Knowledge and attitudes on pharmacogenetics among pediatricians. <b>2020</b> , 65, 437-444		25
277	Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen. <b>2020</b> , 146, 1395-1404		15
276	Added Value of Clinical Sequencing: WGS-Based Profiling of Pharmacogenes. <b>2020</b> , 21,		16
275	Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical Settings. <b>2021</b> , 61, 65-84		7

274	Global distribution of CYP2C19 risk phenotypes affecting safety and effectiveness of medications. <b>2021</b> , 21, 190-199		3
273	Retrospective Review of Pharmacogenetic Testing at an Academic Children’s Hospital. <b>2021</b> , 14, 412-421		5
272	Pharmacogenetics at Scale: An Analysis of the UK Biobank. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 109, 1528-1537	6.1	23
271	EpiGraphDB: a database and data mining platform for health data science. <b>2021</b> , 37, 1304-1311		5
270	Democratizing genomics: Leveraging software to make genetics an integral part of routine care. <b>2021</b> , 187, 14-27		2
269	Pharmacogenomics: Prescribing based on genetic variation. <b>2021</b> , 14, 116-123		
268	First Report of Pharmacogenomic Profiling in an Outpatient Spine Setting: Preliminary Results from a Pilot Study. <b>2021</b> , 145, e21-e31		1
267	Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review. <b>2021</b> , 17, 9-21		6
266	Beyond medically actionable results: an analytical pipeline for decreasing the burden of returning all clinically significant secondary findings. <i>Human Genetics</i> , <b>2021</b> , 140, 493-504	6.3	4
265	CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders. <b>2021</b> , 31, 56-62		3
264	Pediatric pharmacogenomics: challenges and opportunities: on behalf of the Sanford Children’s Genomic Medicine Consortium. <b>2021</b> , 21, 8-19		8
263	Combination of Genome-Wide Polymorphisms and Copy Number Variations of Pharmacogenes in Koreans. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6	1
262	The ADME Encyclopedia. <b>2021</b> , 1-10		
261	Pharmacogenetics and personalized medicine. <b>2021</b> , 193-219		
260	Potential of whole-genome sequencing-based pharmacogenetic profiling. <i>Pharmacogenomics</i> , <b>2021</b> , 22, 177-190	2.6	5
259	Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 179-188	6.1	9
258	Neptune: An environment for the delivery of genomic medicine.		1
257	Actionable pharmacogenetic variants in Hong Kong Chinese exome sequencing data and projected prescription impact in the Hong Kong population. <b>2021</b> , 17, e1009323		5

256	Anatomical distribution and expression of CYP in humans: Neuropharmacological implications. <b>2021</b> , 82, 628-667		4
255	Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. <b>2021</b> , 13,		7
254	Integrating pharmacogenetic testing via medication therapy management in an outpatient family medicine clinic. <i>Pharmacogenomics</i> , <b>2021</b> , 22, 203-212	2.6	2
253	Pathway to Ascertain the Role of Pharmacogenomics in Healthcare Utilization Outcomes [Letter]. <b>2021</b> , 14, 379-380		1
252	Massively parallel characterization of CYP2C9 variant enzyme activity and abundance.		2
251	Strategies to Improve the Clinical Outcomes for Direct-to-Consumer Pharmacogenomic Tests. <b>2021</b> , 12,		3
250	Potentially actionable pharmacogenetic variants and symptom control medications in oncology. <b>2021</b> , 29, 5927-5934		1
249	Sequence2Script: A Web-Based Tool for Translation of Pharmacogenetic Data Into Evidence-Based Prescribing Recommendations. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 636650	5.6	6
248	PharmaKU: A Web-Based Tool Aimed at Improving Outreach and Clinical Utility of Pharmacogenomics. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6	0
247	The Implementation Science for Genomic Health Translation (INSIGHT) Study in Epilepsy: Protocol for a Learning Health Care System. <b>2021</b> , 10, e25576		
246	A retrospective analysis of actionable pharmacogenetic/genomic biomarker language in FDA labels. <b>2021</b> , 14, 1412-1422		1
245	Adolescent perceptions of pharmacogenetic testing. <i>Pharmacogenomics</i> , <b>2021</b> , 22, 335-343	2.6	0
244	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <b>2021</b> , 43, 150-200		17
243	Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS). <b>2021</b> , 19, 151		2
242	Update on next generation sequencing of pharmacokinetics-related genes: Development of the PKseq panel, a platform for amplicon sequencing of drug-metabolizing enzyme and drug transporter genes. <b>2021</b> , 37, 100370		1
241	Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice. <b>2021</b> , 5,		6
240	Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies. <b>2021</b> , 19, 813-831		1
239	Implementation of Pharmacogenomics and Artificial Intelligence Tools for Chronic Disease Management in Primary Care Setting. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6	4



238	Interplay between IL6 and CRIM1 in thiopurine intolerance due to hematological toxicity in leukemic patients with wild-type NUDT15 and TPMT. <b>2021</b> , 11, 9676		1
237	Pharmacogenetic genotype and phenotype frequencies in a large Danish population-based case-cohort sample. <b>2021</b> , 11, 294		4
236	Pharmacogenetics to guide cardiovascular drug therapy. <b>2021</b> , 18, 649-665		5
235	Contribution of the Gut Microbiome to Drug Disposition, Pharmacokinetic and Pharmacodynamic Variability. <b>2021</b> , 60, 971-984		5
234	Patients with geographic barriers to health care access are prescribed a higher proportion of drugs with pharmacogenetic testing guidelines. <b>2021</b> , 14, 1841-1852		0
233	A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors. <b>2021</b> , 7, 19		4
232	Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel- Example. <b>2021</b> , 14, 569-577		3
231	Pharmacogenomics-guided supportive oncology: A tale of two trials. <b>2021</b> , 105, 106391		1
230	Global spectrum of population-specific common missense variation in cytochrome P450 pharmacogenes. <i>Human Mutation</i> , <b>2021</b> , 42, 1107-1123	4-7	
229	Analytical validation of a laboratory-development multigene pharmacogenetic assay. <b>2021</b> , 31, 177-184		0
228	Validation of a Large Custom-Designed Pharmacogenomics Panel on an Array Genotyping Platform. <b>2021</b> , 6, 1505-1516		0
227	Pharmacogenomics in Cardiovascular Diseases. <b>2021</b> , 1, e189		0
226	Translational Pharmacogenomics: Discovery, Evidence Synthesis and Delivery of Race-Conscious Medicine. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 909-925	6.1	2
225	Drug-Drug-Gene Interactions: A Call for Clinical Consideration. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 549-551	6.1	1
224	Neptune: an environment for the delivery of genomic medicine. <b>2021</b> , 23, 1838-1846		1
223	An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 563-572	6.1	60
222	Moving Pharmacogenetics Into Practice: It's All About the Evidence!. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 649-661	6.1	6
221	Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. <b>2021</b> , 23, 2335-2341		5

220	Characteristics of adverse drug reactions associated with antiepileptics at a tertiary children's hospital in Japan: A retrospective observational cohort study. <b>2021</b> , 173, 106614		1
219	Technological readiness and implementation of genomic-driven precision medicine for complex diseases. <b>2021</b> , 290, 602-620		6
218	Key considerations in the pharmacological management of treatment-resistant depression. <b>2021</b> , 22, 2405-2415		0
217	Genomewide Association Studies in Pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 637-648	6.1	5
216	Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application. <b>2021</b> , 21, 691-711		0
215	The Role of Electronic Health Records in Advancing Genomic Medicine. <i>Annual Review of Genomics and Human Genetics</i> , <b>2021</b> , 22, 219-238	9.7	2
214	Pharmacogenomic Clinical Decision Support: A Review, How-to Guide, and Future Vision. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> ,	6.1	1
213	Perception of personalized medicine, pharmacogenomics, and genetic testing among undergraduates in Hong Kong. <b>2021</b> , 15, 54		2
212	Pharmacogenomic testing to support prescribing in primary care: a structured review of implementation models. <i>Pharmacogenomics</i> , <b>2021</b> , 22, 761-776	2.6	1
211	Pilot study of multi-gene pharmacogenetic testing for pain management in oncology palliative medicine. <i>Pharmacogenomics</i> , <b>2021</b> , 22, 737-748	2.6	1
210	Towards population-specific pharmacogenomics in the era of next-generation sequencing. <b>2021</b> , 26, 1776-1783		1
209	Pharmacogenomics in cancer supportive care: key issues and future directions. <b>2021</b> , 29, 6187-6191		0
208	Comparison of clinical pharmacogenetic recommendations across therapeutic areas. <b>2021</b> ,		0
207	PriME-PGx: La Princesa University Hospital Multidisciplinary Initiative for the Implementation of Pharmacogenetics. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2
206	Individualized Drugs' Selection by Evaluation of Drug Properties, Pharmacogenomics and Clinical Parameters: Performance of a Bioinformatic Tool Compared to a Clinically Established Counselling Process. <b>2021</b> , 14, 955-962		0
205	Applying Next-Generation Sequencing Platforms for Pharmacogenomic Testing in Clinical Practice. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 693453	5.6	6
204	Measuring Pharmacogene Variant Function at Scale Using Multiplexed Assays. <b>2021</b> ,		2
203	Psychotropic prescribing rates and pharmacogenomic testing implications for autism in the Canadian primary care sentinel surveillance network. <b>2021</b> ,		

202	Real-World Evaluation of Universal Germline Screening for Cancer Treatment-Relevant Pharmacogenes. <b>2021</b> , 13,		0
201	Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations. <b>2021</b> , 22,		2
200	Clinical Implications of Combinatorial Pharmacogenomic Tests Based on Cytochrome P450 Variant Selection. <b>2021</b> , 12, 719671		1
199	Substrate specificity of CYP2D6 genetic variants. <i>Pharmacogenomics</i> , <b>2021</b> , 22, 1081-1089	2.6	1
198	Massively parallel characterization of CYP2C9 variant enzyme activity and abundance. <b>2021</b> , 108, 1735-1751		12
197	Clinical implementation of drug metabolizing gene-based therapeutic interventions worldwide. <i>Human Genetics</i> , <b>2021</b> , 1	6.3	1
196	Indo-Swiss symposium on advances in pharmacogenomic strategies for implementation of personalized medicine. <i>Pharmacogenomics</i> , <b>2021</b> , 22, 67-71	2.6	1
195	Translational pharmacogenetics: pharmacogenetically driven clinical decision making. <b>2021</b> , 71-83		
194	The ADME Encyclopedia. <b>2021</b> , 1-8		
193	Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. <b>2020</b> , 3, e2029411		10
192	Variable Drug Response: Genetic Evaluation.		2
191	Precision Dosing: The Clinical Pharmacology of Goldilocks. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 109, 11-14	6.1	2
190	DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation. <b>2020</b> , 40, 1108-1129		6
189	Pharmacogenetics of antipsychotic treatment in schizophrenia. <b>2014</b> , 1175, 557-87		19
188	Personalized Medicine. <b>2016</b> , 4235-4249		1
187	Individualized Treatment Strategy for Depressive Disorder. <b>2019</b> , 1180, 219-232		3
186	Frequencies of Genetic Polymorphisms of Clinically Relevant Gene-Drug Pairs in a German Psychiatric Inpatient Population. <i>Pharmacopsychiatry</i> , <b>2021</b> , 54, 81-89	2	3
185	Identification of high-impact gene-drug pairs for pharmacogenetic testing in Alberta, Canada. <b>2021</b> , 31, 29-39		3

184	Pharmacogenetics at scale: An analysis of the UK Biobank.	2
183	Drug Response Pharmacogenetics for 200,000 UK Biobank Participants.	3
182	Characterizing Pharmacogenetic Testing Among Children's Hospitals. <b>2021</b> , 14, 692-701	7
181	Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection. <b>2020</b> , 8, 23	4
180	Pharmacogenomics in dermatology: tools for understanding gene-drug associations. <b>2019</b> , 38, E19-E24	3
179	Where Failure Is Not an Option -Personalized Medicine in Astronauts. <b>2015</b> , 10, e0140764	19
178	Virtual Pharmacist: A Platform for Pharmacogenomics. <b>2015</b> , 10, e0141105	7
177	ePGA: A Web-Based Information System for Translational Pharmacogenomics. <b>2016</b> , 11, e0162801	12
176	Exploring public genomics data for population pharmacogenomics. <b>2017</b> , 12, e0182138	26
175	Pharmacogenetics implementation in the clinics: information and guidelines for germline variants.. <b>2019</b> , 2, 53-68	4
174	Importance of CYP2D6 genotype/activity testing and applications. <b>2014</b> , 118-133	1
173	Genetics and pharmacogenetics in the diagnosis and therapy of cardiovascular diseases. <b>2019</b> , 90, 7-19	2
172	Pharmacogenetics and outcome with antipsychotic drugs. <b>2014</b> , 16, 555-66	51
171	Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines Part 2. <b>2016</b> , 6, 193	3
170	How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?. <b>2020</b> , 11, 491895	10
169	Precision Population Medicine in Primary Care: The Sanford Chip Experience. <b>2021</b> , 12, 626845	6
168	Pharmacogenomics, How to Deal with Different Types of Variants in Next Generation Sequencing Data in the Personalized Medicine Area. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 10,	5.1 2
167	Toward Integrating Healthcare Data and Systems. <b>2016</b> , 270-304	5

166	A conceptual model for translating omic data into clinical action. <b>2015</b> , 6, 46		15
165	Harnessing pharmacological knowledge for personalized medicine and pharmacotyping: Challenges and lessons learned. <b>2014</b> , 3, 110		2
164	The role of pharmacogenetics in the treatment of anxiety disorders and the future potential for targeted therapeutics. <b>2021</b> , 17, 1249-1260		1
163	Pharmacogenomics: A road ahead for precision medicine in psychiatry. <b>2021</b> ,		1
162	Validation of a multi-gene qPCR-based pharmacogenomics panel across major ethnic groups in Singapore and Indonesia. <i>Pharmacogenomics</i> , <b>2021</b> , 22, 1041-1056	2.6	1
161	Pharmacogenomics in psychiatry and neurology: Bridging research and clinical practice. <b>2012</b> , 1, 213-216		
160	Pharmacogenomics of adverse effects of anti-leukemic agents in children. <b>2012</b> , 17, 7-11		1
159	Pharmacogenetics and Antineoplastic Therapies. <b>2015</b> , 275-305		
158	Implementation of Genomic Medicine: Tools and Challenges. <b>2015</b> , 329-347		
157	Ethical Considerations in the Genomic Era. <b>2015</b> , 349-375		0
156	Personalized Medicine. <b>2015</b> , 1-16		
155	Essential Pharmacogenomic Biomarkers in Clinical Practice. <b>2016</b> , 51-74		
154	Pharmacogenomics and Cardiovascular Disease. <b>2017</b> , 161-174		
153	Charting a Course for Genomic Medicine from Base Pair to Bedside. <b>2018</b> , 215-225		
152	Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application. <b>2018</b> , 1,		4
151	Whole genome sequencing identifies high-impact variants in well-known pharmacogenomic genes.		0
150	Pharmacogenomics and Cardiovascular Disease. <b>2019</b> , 184-197		
149	Toward Integrating Healthcare Data and Systems. <b>2019</b> , 740-773		

- 148 A Multiplex Pharmacogenetics Assay using the MinION Nanopore Sequencing Device.
- 147 Fundamentals of Drug Metabolism and Pharmacogenomics Within a Learning Healthcare System Workflow Perspective. **2020**, 59-80
- 146 Pharmacogenomics in Perioperative Care. **2020**, 117-127
- 145 EpiGraphDB: A database and data mining platform for health data science. ○
- 144 Pharmacogenetics in Cancer Treatment: Challenges and Recent Trends. **2020**, 423-430
- 143 Biochip-based approach for comprehensive pharmacogenetic testing. **2020**, ○
- 142 Pharmacogenomic mechanisms of drug toxicity. **2022**, 303-322
- 141 An Architectural Solution for Health Information Exchange. **2020**, 283-327
- 140 Genetic Disorders. **2020**, 1-15
- 139 Development and Implementation of In-House Pharmacogenomic Testing Program at a Major Academic Health System. **2021**, 12, 712602 ○
- 138 Plasma Carboxylesterase 1 Predicts Methylphenidate Exposure: A Proof-of-Concept Study Using Plasma Protein Biomarker for Hepatic Drug Metabolism. *Clinical Pharmacology and Therapeutics*, **2021**, 6.1 ○
- 137 Interplay of IL6 and CRIM1 on thiopurine-induced neutropenia in leukemic patients with wild-type NUDT15 and TPMT.
- 136 Implementing Primary Care Mediated Population Genetic Screening within an Integrated Health System.
- 135 Current Mesothelioma Treatment and Future Perspectives.
- 134 An RDF/OWL knowledge base for query answering and decision support in clinical pharmacogenetics. **2013**, 192, 539-42 6
- 133 Adverse Drug Event-based Stratification of Tumor Mutations: A Case Study of Breast Cancer Patients Receiving Aromatase Inhibitors. **2014**, 2014, 1160-9 3
- 132 A Template for Authoring and Adapting Genomic Medicine Content in the eMERGE Infobutton Project. **2014**, 2014, 944-53 7
- 131 Creating Shareable Clinical Decision Support Rules for a Pharmacogenomics Clinical Guideline Using Structured Knowledge Representation. **2015**, 2015, 1985-94 2

130	GT2RDF: Semantic Representation of Genetic Testing Data. <b>2016</b> , 2016, 1060-1069		1
129	. <b>2020</b> , 66, 247-249		
128	Pharmacogenomic testing: Enhancing personalized medication use for patients. <b>2020</b> , 66, 241-243		1
127	Drug Response Pharmacogenetics for 200,000 UK Biobank Participants. <b>2021</b> , 26, 184-195		6
126	United States Emergency Department Use of Medications with Pharmacogenetic Recommendations. <b>2021</b> , 22, 1347-1354		1
125	Life-time Actionable Pharmacogenetic Drug Use: A Population-based Cohort Study in 86 040 Young People With and Without Mental Disorders in Denmark. <i>Pharmacopsychiatry</i> , <b>2021</b> ,	2	0
124	Genetic Polymorphism of Drug Metabolic Gene and of Five Ethnic Minorities in Heilongjiang Province, Northeast China. <b>2021</b> , 14, 1537-1547		
123	Role of the gut microbiome in cardiovascular drug response: The potential for clinical application. <b>2021</b> ,		0
122	Building an information system to facilitate pharmacogenomics clinical translation with clinical decision support. <i>Pharmacogenomics</i> , <b>2021</b> ,	2.6	0
121	Pharmacogenomic analysis of a genetically distinct Indigenous population. <b>2021</b> ,		0
120	VARIABILITY OF DRUG RESPONSE: APPROACH TO MINIMIZE TOXICITY AND MAXIMIZE EFFICACY. <b>2016</b> , 53, 5-10		6
119	Keeping pace with haplotype discovery: innovative methods to assign function.. <i>Pharmacogenomics</i> , <b>2022</b> ,	2.6	
118	Assessment of a Manual Method versus an Automated, Probability-Based Algorithm to Identify Patients at High Risk for Pharmacogenomic Adverse Drug Outcomes in a University-Based Health Insurance Program.. <i>Journal of Personalized Medicine</i> , <b>2022</b> , 12,	3.6	0
117	Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies.. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 834129	5.6	0
116	Functional coding haplotypes and machine-learning feature elimination identifies predictors of Methotrexate Response in Rheumatoid Arthritis patients.. <b>2022</b> , 103800		0
115	Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population.. <b>2022</b> , 17, e0263137		2
114	Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.. <b>2022</b> ,		1
113	Interventional cardiologists' attitudes towards pharmacogenetic testing and impact on antiplatelet prescribing decisions. <b>2021</b> ,		

112	Automated Pharmacogenomic Reports for Clinical Genome Sequencing.. <b>2022,</b>	0
111	Genetic Disorders. <b>2022,</b> 207-221	
110	Reducing severe cutaneous adverse and type B adverse drug reactions using pre-stored human leukocyte antigen genotypes.. <b>2022,</b> 12, e12098	1
109	Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy in Children with Cancer: A Systematic Review and Meta-Analysis.. <b>2022,</b> 14,	1
108	Pharmacy Student Perceptions of a Virtual Pharmacogenomics Activity.. <b>2022,</b> 10,	1
107	Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG).. <b>2022,</b>	0
106	Pharmacogenomic testing in paediatrics: clinical implementation strategies.. <b>2021,</b>	1
105	An Investigation of the Knowledge Overlap between Pharmacogenomics and Disease Genetics. <b>2022,</b> 27, 385-396	0
104	Pharmacogenomics and antipsychotics: efficacy and adverse drug reactions. <b>2022,</b> 161-188	0
103	Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.. <b>2022,</b> 7, 12	1
102	PacBio long-read amplicon sequencing enables scalable high-resolution population allele typing of the complex CYP2D6 locus.. <b>2022,</b> 5, 168	0
101	Clinical Importance of Potential Genetic Determinants Affecting Propofol Pharmacokinetics and Pharmacodynamics.. <b>2022,</b> 9, 809393	0
100	Maximizing Time Efficiencies with an End-to-End Automated Clinical Workflow for Pharmacogenomics Testing. <b>2022,</b> 9, 50-51	
99	A population study of clinically actionable genetic variation affecting drug response from the Middle East.. <b>2022,</b> 7, 10	5
98	Modern developments in germline pharmacogenomics for oncology prescribing.. <b>2022,</b>	0
97	Pharmacogenetics research in Brazil: a systematic review.. <i>Pharmacogenomics,</i> <b>2022,</b>	2.6
96	Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review.. <b>2022,</b> 1	1
95	Pharmacogenomics implementation and multidisciplinary genomics collaboration: Real-world experience from Geisinger.. <i>American Journal of Health-System Pharmacy,</i> <b>2022,</b>	2.2



94	Exploring the Kinh Vietnamese genomic database for the polymorphisms of the P450 genes toward precision public health.. <i>Annals of Human Biology</i> , <b>2022</b> , 1-13	1.7	
93	Real-World Impact of a Pharmacogenomics-Enriched Comprehensive Medication Management Program.. <i>Journal of Personalized Medicine</i> , <b>2022</b> , 12,	3.6	0
92	From pharmacogenetics to pharmaco-omics: Milestones and future directions.. <i>Human Genetics and Genomics Advances</i> , <b>2022</b> , 3, 100100	0.8	1
91	Pharmacogenetics of clopidogrel and warfarin in the treatment of cardiovascular diseases: an overview of reviews.. <i>Pharmacogenomics</i> , <b>2022</b> ,	2.6	0
90	PharmVIP: A Web-Based Tool for Pharmacogenomic Variant Analysis and Interpretation. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6	0
89	Man vs. machine: comparison of pharmacogenetic expert counselling with a clinical medication support system in a study with 200 genotyped patients.. <i>European Journal of Clinical Pharmacology</i> , <b>2021</b> , 78, 579	2.8	0
88	Harmonizing variant classification for return of results in the All of Us Research Program.. <i>Human Mutation</i> , <b>2021</b> ,	4.7	
87	Prescription Patterns and Relationship to Pharmacogenomics Testing in the Military Health System.. <i>Military Medicine</i> , <b>2021</b> , 187, 9-17	1.3	
86	The Future of Personalized Medicine in Space: From Observations to Countermeasures.. <i>Frontiers in Bioengineering and Biotechnology</i> , <b>2021</b> , 9, 739747	5.8	4
85	Evaluating an interactive teaching approach with personal genotyping to provide pharmacy students with a knowledge base for clinical pharmacogenetics. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , <b>2021</b> , 4, 343-351	1.4	
84	The Pharmacogenetics of Opiates and Its Impact on Delirium in Mechanically Ventilated Adults: A Pilot Study. <i>Journal of Pharmacy Technology</i> , 875512252210851	0.6	
83	Table_1.pdf. <b>2019</b> ,		
82	Table_2.pdf. <b>2019</b> ,		
81	Table_1.pdf. <b>2020</b> ,		
80	Table_1.docx. <b>2019</b> ,		
79	DataSheet_1.docx. <b>2019</b> ,		
78	Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country.. <i>Iranian Journal of Pharmaceutical Research</i> , <b>2021</b> , 20, 92-106	1.1	
77	The Prevalence of Pharmacogenomics Variants and Their Clinical Relevance Among the Pakistani Population.. <i>Evolutionary Bioinformatics</i> , <b>2022</b> , 18, 11769343221095834	1.9	

76	Leverage drug perturbation to reveal genetic regulators of hepatic gene expression in African Americans.		
75	Pharmacogenetic gene-drug associations in pediatric burn and surgery patients. <i>Journal of Burn Care and Research</i> ,	0.8	0
74	Effects of Pharmacogenomic Testing in Clinical Pain Management: Retrospective Study. <i>Jmirx Med</i> , <b>2022</b> , 3, e32902	0.2	3
73	Advancing Pharmacogenomics from Single-Gene to Preemptive Testing.. <i>Annual Review of Genomics and Human Genetics</i> , <b>2022</b> ,	9.7	1
72	A Roadmap for Future Parkinson's Pharmacogenomics in Asia. <i>Frontiers in Aging Neuroscience</i> , <b>2022</b> , 14,	5.3	
71	Drug metabolic enzyme genotype-phenotype discrepancy: High phenoconversion rate in patients treated with antidepressants. <i>Biomedicine and Pharmacotherapy</i> , <b>2022</b> , 152, 113202	7.5	2
70	Overview of effective pharmacogenomic clinical decision support. <b>2022</b> , 3-18		
69	Pharmacogenomics: Challenges and Future Perspectives. <b>2022</b> , 883-890		
68	Scientific evidence and sources of knowledge for pharmacogenomics. <b>2022</b> , 19-51		
67	A learning health system approach to delivery and adoption of clinical decision support. <b>2022</b> , 241-257		
66	Pharmacogenomics: Basis and Milestones. <b>2022</b> , 874-883		
65	Impact of Immunosuppressive Drugs on Fibroblasts: An In Vitro Study. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11, 3107	5.1	
64	Pharmacogenomic Profile of Amazonian Amerindians. <i>Journal of Personalized Medicine</i> , <b>2022</b> , 12, 952	3.6	0
63	A comprehensive genomic reporting structure for communicating all clinically significant primary and secondary findings. <i>Human Genetics</i> ,	6.3	
62	Approaches and hurdles of implementing pharmacogenetic testing in the psychiatric clinic. <b>2022</b> , 1,		
61	Personalized Medicine for the Critically Ill Patient: A Narrative Review. <i>Processes</i> , <b>2022</b> , 10, 1200	2.9	0
60	Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic Model. <i>Frontiers in Pharmacology</i> , 13,	5.6	
59	Effects of Pharmacokinetic Gene Variation on Therapeutic Drug Levels and Antidepressant Treatment Response. <i>Pharmacopsychiatry</i> ,	2	1

- 58 ClinPharmSeq: A targeted sequencing panel for clinical pharmacogenetics implementation. **2022**, 17, e0272129 ○
- 57 An Overview Regarding Pharmacogenomics And Biomarkers Discovery: Focus On Breast Cancer. **2022**, 22, ○
- 56 Comprehensive characterization of pharmacogenes in a Taiwanese Han population. 13, ○
- 55 Real-World Evaluation of a Population Germline Genetic Screening Initiative for Family Medicine Patients. **2022**, 12, 1297 ○
- 54 Pharmacogenetic testing-guided treatment for oncology: an overview of reviews. 1
- 53 Principles of Pharmacogenomics and Pharmacogenetics. **2022**, 13-32 ○
- 52 Using Genome Wide Studies to Generate and Test Hypotheses that Provide Mechanistic Details of How Synonymous Codons Affect Protein Structure and Function: Functional SNPs in the Age of Precision Medicine. **2022**, 171-183 ○
- 51 Pharmacogenomics in Cytotoxic Chemotherapy of Cancer. **2022**, 63-94 ○
- 50 Polymorphisms in drug-metabolizing enzymes: Challenges and strategies. **2022**, 347-374 ○
- 49 Pharmacogenetics of Antipsychotic Treatment in Schizophrenia. **2022**, 389-425 ○
- 48 Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population. ○
- 47 Implementing Comprehensive Pharmacogenomics in a Community Hospital Associated Primary Care Setting. **2022**, ○
- 46 A survey of physician opinions in Russia in the field of pharmacogenetics of cardiovascular disease. 00-00 ○
- 45 Pharmacogenetic profiling via genome sequencing in children with medical complexity. ○
- 44 Development and application of a computable genotype model in the GA4GH Variation Representation Specification. ○
- 43 Lessons learned during the process of reporting individual genomic results to participants of a population-based biobank. ○
- 42 Maturing pharmacogenomic factors deliver improvements & cost efficiencies. 1-26 ○
- 41 Barriers to genetic testing in clinical psychiatry and ways to overcome them: from clinicians' attitudes to sociocultural differences between patients across the globe. **2022**, 12, ○

40	Pharmacogenes that demonstrate high association evidence according to CPIC, DPWG, and PharmGKB. 9,	0
39	Integrating pharmacogenomics into precision pain management.	1
38	Rates of Divergent Pharmacogenes in a Psychiatric Cohort of Inpatients with Depression Arguments for Preemptive Testing. <b>2022</b> , 12, 317-328	0
37	Pharmacogenomics in the era of personalised medicine.	0
36	Local ancestry-informed candidate pathway analysis of warfarin stable dose in latino populations.	0
35	Pharmacogenomics of medications given via nonconventional administration routes: a scoping review.	0
34	DrugDrugGene Interactions in Cardiovascular Medicine. Volume 15, 879-911	0
33	Pharmacogenomics in Stroke and Cardiovascular Disease: State of the Art.	0
32	How to Run the Pharmacogenomics Clinical Annotation Tool ( PharmCAT ).	0
31	Prescriber Adoption of SLCO1B1 Genotype-Guided Simvastatin Clinical Decision Support in a Clinical Pharmacogenetics Program.	0
30	Genome screening, reporting, and genetic counseling for healthy populations.	0
29	Implementation of Pharmacogenomics Where are we now?.	0
28	Interrogating the Human Diplome: Computational Methods, Emerging Applications, and Challenges. <b>2023</b> , 1-30	0
27	Precision Medicine Using Pharmacogenomic Panel-Testing. <b>2022</b> , 42, 587-602	1
26	Building Evidence for Clinical Use of Pharmacogenomics and Reimbursement for Testing. <b>2022</b> , 42, 533-546	1
25	Improving prescribing: a feasibility study of pharmacogenetic testing with clinical decision support in primary healthcare in Singapore.	0
24	Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population. <b>2022</b> , 20,	0
23	Delineating geneEnvironment effects using virtual twins of patients treated with clozapine.	0

22	Multi-omics studies in historically excluded populations: the road to equity.	1
21	Pediatric Considerations for Pharmacogenetic Selective Serotonin Reuptake Inhibitors Clinical Decision Support.	0
20	Integration of a pharmacist-led pharmacogenomic service in a geriatric clinic: Barriers and outcomes. <b>2023</b> ,	0
19	Deciphering genetic causes for sex differences in human health through drug metabolism and transporter genes. <b>2023</b> , 14,	1
18	Pharmacogenetics of P2Y 12 receptor inhibitors.	0
17	Leveraging drug perturbation to reveal genetic regulators of hepatic gene expression in African Americans. <b>2023</b> , 110, 58-70	0
16	CYP2D6 pharmacogenetics and phenoconversion in personalized medicine. <b>2022</b> , 18, 769-785	0
15	Evidence on the Impact of Pharmacogenetics to Treat and Manage Asthma. <b>2022</b> , 1-15	0
14	Genotype and Phenotype Influence the Personal Response to Prostaglandin Analogues and Beta-Blockers in Spanish Glaucoma and Ocular Hypertension Patients. <b>2023</b> , 24, 2093	0
13	PAnno: A pharmacogenomics annotation tool for clinical genomic testing. 14,	0
12	Interdisciplinary Collaboration Among Nursing and Computer Science to Refine a Pharmacogenetics Clinical Decision Support Tool Via Mobile Application. Publish Ahead of Print,	0
11	What Is Precision Medicine?. <b>2023</b> , 8, 371-390	0
10	The prevalence of pharmacogenetic variants of vitamin K epoxide reductase complex subunit 1 gene (rs9923231), cytochrome P450 family 2 subfamily C member 9 gene (rs1799853) and cytochrome P450 family 3 subfamily-A member-5 gene (rs776746) among 13 ethnic groups of Pakistan.	0
9	Practice of CYP450 genotyping and phenotyping in children in a real-life setting. 14,	0
8	A review of pharmacogenetic studies in the Bangladeshi population. <b>2020</b> ,	0
7	Development of Novel Mass Spectrum-Based Assay for Simultaneous Detection of 36 Variants in the 14 Pharmacogenetic Genes for the Japanese Population. <b>2023</b> , 46, 511-516	0
6	Predictive modeling of adverse events of tamoxifen therapy for breast cancer (results of a cohort study). <b>2023</b> , 63-73	0
5	Polypharmacy and precision medicine. <b>2023</b> , 1,	0

- 4 A retrospective analysis of preemptive pharmacogenomic testing in 22,918 individuals from China. **2023**, 37,
- 3 Pharmacogenomic and Statistical Analysis. **2023**, 305-330
- 2 A Comprehensive Analysis of 21 Actionable Pharmacogenes in the Spanish Population: From Genetic Characterisation to Clinical Impact. **2023**, 15, 1286
- 1 Use of a multi-gene pharmacogenetic panel reduces adverse drug effects. **2023**, 101021